Komori
Share Issuance and Disposal4576D.Western Therapeutics Institute, Inc.Pharmaceuticals

Notice Regarding Completion of the Acquisition and Cancellation of the 13th Stock Acquisition Rights and Monthly Exercise Status

During September, 400 of the 13th Series of Stock Acquisition Rights were exercised and 40,000 shares were delivered. On 29 September, the company acquired the 7,938 rights that remained and immediately cancelled all of them. The number of stock acquisition rights remaining after the acquisition and cancellation was 0.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
7938
units
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Acquisition and Cancellation of the 13th Series of Stock Acquisition Rights and Report on Monthly Exercise Status

発行・処分する株式数

Number of shares delivered during the month: 40,000 shares (40,000 new shares and 0 shares of treasury stock transferred)

発行済株式総数

Exercise ratio for the month subject to the report against total issued: 0.40%; exercise ratio subject to exercise restrictions: 0.09%

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise price during the month subject to the report: ¥80 or ¥81; adjustment provisions/floor: Not disclosed
Number of Stock Acquisition Rights
Total issued: 100,000 rights (400 rights represent 0.40% of the total issued); unexercised at the end of the month preceding the month subject to the report: 8,338 rights; acquired and cancelled: 7,938 rights; remaining after cancellation: 0 rights
Procedures under the Corporate Code of Conduct
Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
Issuance of the 13th Series of Stock Acquisition Rights based on a resolution of the Board of Directors held on 15 July 2025; amount: Not disclosed
Impact on Business Performance
The acquisition and cancellation of these stock acquisition rights will have no impact on financial results for the current fiscal year.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalAcquisition and Cancellation of the 13th Series of Stock Acquisition Rights and Report on Monthly Exercise Status
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 40,000 shares (40,000 new shares and 0 shares of treasury stock transferred)
Dilution RateExercise ratio for the month subject to the report against total issued: 0.40%; exercise ratio subject to exercise restrictions: 0.09%
Total number of issued shares57,559,412 shares (as of the end of the month preceding the month under review) → Not disclosed
Exercise priceExercise price during the month subject to the report: ¥80 or ¥81; adjustment provisions/floor: Not disclosed
Number of Stock Acquisition RightsTotal issued: 100,000 rights (400 rights represent 0.40% of the total issued); unexercised at the end of the month preceding the month subject to the report: 8,338 rights; acquired and cancelled: 7,938 rights; remaining after cancellation: 0 rights
Procedures under the Corporate Code of ConductDescribes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financingIssuance of the 13th Series of Stock Acquisition Rights based on a resolution of the Board of Directors held on 15 July 2025; amount: Not disclosed
Impact on Business PerformanceThe acquisition and cancellation of these stock acquisition rights will have no impact on financial results for the current fiscal year.
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company has stated that the acquisition and cancellation will have no impact on results for the current fiscal year.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of the Acquisition and Cancellation of the 13th Stock Acquisition Rights and Monthly Exercise Status | D.Western Therapeutics Institute, Inc. (4576) timely disclosure | Komori